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Published literature has suggested that the incidence of Rheumatoid Arthritis (RA) has declined over the last three decades [1] [2] [3] [4] [5] [6] [7] [8] [9] . This corresponds with reports of declines in disease activity 10, 11 , functional disability 12, 13 , orthopaedic surgery 14 and radiographic progression 12, 15, 16 .
While the causes are not entirely clear, it is hypothesised that these declines in disease severity are related to widespread changes in treatment strategies during the 1990s 17 . Radiographic joint damage is often used in RCTs as a primary outcome, and has been shown to be strongly related to levels of functional disability 26 and disease activity 27 .
Although commonly expressed as a global score 28 , radiographic joint damage comprises two main components, erosions and joint space narrowing (JSN). While related, they are thought to be the result of two distinct pathophysiological mechanisms 29, 30 . Possible causes of erosive joint destruction are the products of invading synovium into the boney structures of the joints, and increased osteoclast activity 31 . In contrast, JSN has been hypothesised to reflect cartilage damage as a result of metalloproteinases, which are upregulated by pro-inflammatory 
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Radiographic progression over 25-years 5 cytokines 32 . JSN is common to a range of pathologies, including osteoarthritis (OA), which is a common comorbid condition in people with RA 33 . Despite this, much of the focus of longitudinal data concerning radiographic damage has reported the combination of these two processes as one composite score 29, 30 , for example using the radiographic scoring methods of Ratingen or Larsen, that lack the ability to distinguish progression of erosions and JSN as separate domains 12, 15, 16 .
Further still, rheumatoid factor (RF) status has been strongly associated with worse radiographic progression [34] [35] [36] , however, to date no study has looked at whether the relative strength of this association has changed given the wider demographic changes seen in many other aspects of RA, including disease severity. It might be hypothesised that radiographic measures of RA will show significant changes given declines in disease activity, but whether previously demonstrated risk factors for progression continue to be influential remains unclear.
This study therefore aims to investigate long-term radiographic progression by comparing data from two UK, multi-centre inception cohorts, the Early RA Study (ERAS), which collected patient data from 1986-2001, and the Early RA Network (ERAN), which collected data from 2002-2013. Specifically, this study 1) compares the total SvdH, erosion and JSN scores at baseline and the rate of progression over the first 5-years between the two cohorts, and 2) estimates the association between RF status and radiographic damage at baseline and progression over the first 5-years in ERAS and ERAN.
Patients and Methods
The data used for this study were collected from two longitudinal inception cohorts, Standard clinical, laboratory and radiographic data were collected at baseline, 3 to 6 months, 12 months, and then yearly thereafter. These included the original three variable 44-joint Disease Activity Score (DAS) for ERAS and the DAS28 for ERAN, the Health Assessment Questionnaire (HAQ), Rheumatoid Factor Positivity and haemoglobin level. To enable comparison of disease activity across the two cohorts, the original DAS in ERAS was converted to DAS28 using the formula DAS28 = (1.072*DAS) + 0.938 37 .
Radiographic scoring
Structural joint damage was assessed from plain radiographs using the SvdH scoring method 38 . All 32 centres collected yearly plain x-rays of hands and feet. Radiographs from all 9 centres recruiting from ERAS, and 7/25 (28%) centres from ERAN scored films using the SvdH method.
The SvdH rates radiographic damage based on the prevalence and severity of the erosions in 32 joints in the hands and 12 joints in the feet, and the prevalence and Radiographic progression over 25-years 7 severity of JSN in 30 joints in the hands and 12 joints in the feet. Each joint was rated from 0-5 (or 0-10 for erosions in the joints of the feet) giving a maximum score of 280 for the erosion score and 168 for the JSN score. These scores were combined to give a total SvdH score ranging from 0 to 448.
One person (KJ) scored the radiographs for ERAS, while another person (DMcW) scored the radiographs for ERAN. Each scorer rated the radiographs in chronological order. To assess agreement between the two, both scored a random sub-sample of thirty-nine radiographs from twenty patients from the ERAS cohort at two time- 
Statistical analysis
To assess differences in the use of first-line conventional DMARDs between the two cohorts, the cumulative incidence of time to first DMARD within the first 12 months from first outpatient appointment was estimated. This was estimated for any DMARD use, as well as separate estimates for the two most commonly used first-line DMARDS, methotrexate and sulphazalasine.
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The skewed distributions of radiographic scores derived by the SvdH method renders linear regression inappropriate 39 . Generalised linear regression with a negativebinomial distribution, henceforth negative binomial regression (NBR), was found to achieve best fit to the data, compared with linear and Poisson distributions.
Mixed-effects NBR (MENBR) models allowed for the longitudinal structure of the data to be modelled appropriately, whereby random intercept and time slope parameters were estimated. Cohort membership (either ERAS or ERAN) was the main covariate of interest. Baseline scores, along with yearly measures of SvdH were used in the models to estimate rates at presentation and over the 5-year follow-up.
Missing data is inherent in longitudinal studies. To probe potential selection bias based on the availability of radiographs, baseline characteristics of those with and without radiographic data were compared. Furthermore, protecting against confounding due to missing longitudinal data, mixed-effects models use full information maximum likelihood making use of all available data under the missing at random assumption, so that all patients with data are included.
Time was defined as years from enrolment and was included as a continuous variable with a random slope to allow for the estimation of the annual rate of progression for each patient. RF status was the secondary covariate of interest and entered as a main effect, along with a three-way interaction term with cohort and time to allow for progression rates to be estimated separately by RF status for each cohort. Sensitivity analysis, which substituted cohort membership for year of diagnosis in the model, was used to investigate the effect of calendar year on longterm radiographic progression. Sex, age, DAS28, HAQ, low Hb (<12 for females /<13
for males), months from symptom onset to first rheumatology visit, steroid use prior 
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to first assessment and DMARD use within first 12-months were all entered into the model to control for any potential confounding effects.
Exponentiated regression coefficients of an NBR model are incidence rate ratios (IRR), which are interpreted as the relative increase in the log-count of the dependent variable (i.e. the SvdH score) given a one-unit increase in the respective covariate (e.g. age). To aid interpretation, the results from the models were also expressed as an absolute change in the SvdH score using the estimated mean SvdH, along with 95% Confidence Intervals [95% CI]. This allowed for a more direct interpretation of the effect that each factor had in terms of absolute difference in SvdH units, the percentage of maximum possible damage, and annual progression greater than the minimum clinically important difference of 5 units 40 .
These models were estimated separately for the total SvdH score, JSN and erosion score. All analyses were conducted using Stata (version 14; StataCorp LP, USA).
Results
Of the 2,701 total patients recruited, 1,662 had SvdH data: 1,216 from ERAS and 446 from ERAN. The demographic and baseline clinical characteristics of both ERAS and ERAN patients, including only those with radiographic data, are shown in Table 1 .
Reasons for missing radiographic data included loss of records, unreadable radiographs and loss to follow-up. Patients from ERAS were marginally younger at presentation and had higher DAS28, ESR, HAQ and were more likely to be anaemic at baseline, but the median time from first symptom to first visit was the same. Patient characteristics with recorded radiographic data were similar to the total patients in their respective cohort.
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controlling for baseline BMI found that while increased BMI at baseline was protective of increased radiographic damage over the first 5 years, it did not alter the main cohort effect (results not shown). Figure 2C ). See Table 2 for absolute and relative changes in both JSN and erosion scores between the two cohorts. 
Association of RF status with radiographic progression in ERAS and ERAN
The absolute and relative difference in total SvdH scores for RF+ and RF-patients in both cohorts are given in Table 3 and displayed graphically in Figure 3 . For the total SvdH score, RF+ RA was not significantly associated with increased radiographic damage at baseline, compared to RF-RA, in either ERAS or ERAN. RF+ RA was associated with a 70% increased annual rate of progression, compared to RF-RA, in Our data extend previous findings of reductions in radiographic damage in RA over recent decades 12, 15, 16 . There are two plausible explanations for these findings, both of which are likely to contribute to the reduction in radiographic damage over time.
Firstly, RA may have become milder, and secondly, earlier more intensive treatment may have improved disease outcomes. Our models adjusted for disease severity at baseline, but it remains possible that lower rates of progression in the more recent cohort reflect milder disease. This is supported by the observation of lower SvdH scores in ERAN compared to ERAS at baseline, prior to DMARD initiation, even though the median time from first symptom to first visit was the same for both cohorts. However, the reduction in radiographic progression is likely to also reflect improvements in the treatment of RA, given the earlier and increased use of methotrexate as the first line DMARD observed in ERAN in this study, which is in line with other reports 12, 15, 16, 36 . Increasing evidence from RCTs also support the hypothesis that early, intensive treatment has an important effect on reducing radiographic progression [42] [43] [44] [45] [46] . Seropositive RA has been consistently associated with increased radiographic damage 35, 36 . This study also found that RF+ RA was highly associated with increased radiographic progression. However, when investigating the absolute change in 
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Radiographic progression over 25-years 15 radiographic progression and found seropositive patients displayed higher radiographic progression, compared to seronegative patients 39, 49 . The estimated change in median SvdH score of 0.6 units per year for seropositive over that of seronegative patients provides an estimate similar to this study.
Many RCTs are restricted to seropositive patients only, and previous research has not focused on the effect of seropositivity in the context of reduced radiographic progression in more recent years. The two long-term observational cohorts examined in this study provide a 'real-world' account of patients typically seen in secondary care, and the high patient numbers over the full 5-year follow-up also provides a unique opportunity to provide precise estimates using the modelling techniques outlined 39 . The use of the SvdH score also provides a first look at the two principle components of radiographic damage, erosions and JSN, in detail. Further data from observational studies are needed to ascertain whether reductions in radiographic progression have also resulted in the diminished association with RF status, particularly in the context of anti-CCP seropositive RA, which could be more predictive of radiographic progression when compared to RF 36,50,51 .
Our research is subject to a number of limitations inherent in cohort studies.
Recruiting centres were hosted by enthusiastic clinicians within the UK and, although they might not necessarily reflect people with RA in other contents, or subjected to different treatment regimens, the multicentre recruitment for these cohorts from district general hospitals is likely to be representative of people with RA in the UK.
Radiographs were not available for all participants, and it is possible that those with more severe disease were more likely to have x-rays, increasing the risk of selection bias in our study. However, baseline variables indicated minimal differences 
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between the whole cohorts, and those for whom radiographic data were available.
The impact of such a selection bias would overestimate rates of progression, particularly for ERAN, where data were less complete; hence our estimates should be treated as conservative.
This study provides further evidence into the marked reduction in radiographic damage over the last 25-years, while providing accurate, quantified estimates of the extent of that reduction. JSN was the major driver for the overall reductions seen, and highlights the importance of investigating JSN and erosions separately when investigating radiographic damage. Advances in treatment are likely to be the main cause for the decline, and adequate DMARD treatment might remove the predictive value of RF status for radiographic progression in early RA. Further research should seek other predictors and mediators if residual radiographic progression despite DMARD treatment is to be halted. The impact of these reductions on patients of varying disease severity, and whether these reductions have an impact on improved long-term functional disability will be crucial in fully realising the impact of these results on clinical care.
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